If you live in the UK and you are looking into semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro), the first question is usually about money. But the NHS does not work like the systems in much of Europe, where access turns on a reimbursement percentage. On the NHS, the real gate is eligibility and capacity. Whether you can get a GLP-1 medication for weight management depends on your clinical situation and on how far the phased national rollout has reached, not on what share of the price is covered.
This guide sets out where access stands in 2026, written for readers in the UK. We keep it current and review it every month, because the rollout is widening in stages and the eligibility gates move. If you want the clinical background first, our comprehensive guide to GLP-1 medications covers what these drugs are, how they work, and who they are approved for in Europe. For the everyday side of treatment, including how diet and fiber help with the side effects, see our complete guide to fiber and GLP-1 medications.
How does the NHS fund GLP-1 medication for weight loss?
The NHS does not reimburse a fraction of a privately bought prescription. Instead it commissions the medication through its own services for patients who meet defined criteria. The National Institute for Health and Care Excellence (NICE) recommends which patients should be treated, and NHS England decides how that recommendation is rolled out in practice given limited capacity.
The result is a staged system. Both tirzepatide (Mounjaro) and semaglutide (Wegovy) are recommended for eligible adults living with obesity who also have weight-related health problems, including high blood pressure, abnormal blood fats, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. But “recommended” and “available to you this month” are not the same thing.
Who can get tirzepatide (Mounjaro) on the NHS in 2026?
From 23 March 2025, tirzepatide for weight management may only be prescribed where a specialist weight management service judges it appropriate, and it is being phased into primary care, meaning GP practices, gradually.
The rollout starts with the highest clinical need. In the initial stage, the people eligible to access tirzepatide through primary care are those living with obesity who have been diagnosed with four of the listed weight-related conditions and who have a BMI of 40 or more, adjusted for ethnicity. Patients who receive it this way also get “wraparound care”, which is dietary and physical activity support alongside the medication.
NHS England has said this staged approach is about delivering the service safely and letting the NHS plan for rising numbers while building skills across the workforce. NICE has committed to reviewing access at three years to decide how it widens and who it covers next. Because the eligibility gate is being opened in stages, it is worth checking your local integrated care board (ICB) for the criteria that apply where you live, since these can differ by area.
Who can get semaglutide (Wegovy) on the NHS?
Semaglutide (Wegovy) follows a different door. It can only be prescribed through a specialist weight management service, not by a GP alone. A doctor might recommend it when diet and exercise changes have not worked on their own.
Eligibility generally requires a BMI of 35 or more, or 32.5 or more for people of Asian, Chinese, Middle Eastern, Black African or African-Caribbean origin. There is also a route for a BMI of 30 to 34.9, or 27.5 to 32.4 with ethnic adjustment, where other criteria are met and the patient is treated by a specialist service. As with tirzepatide, exactly who can be treated depends on the integrated care board.
What about diabetes?
The picture is different for type 2 diabetes. Tirzepatide (Mounjaro) can be prescribed for diabetes management in specific circumstances, separately from the obesity route. Semaglutide is long established on the NHS for type 2 diabetes; NHS prescriptions of Ozempic are for diabetes, not for weight loss, although a GP can write a private off-label prescription for weight management.
The practical takeaway: a GLP-1 prescribed on the NHS for diabetes is a different pathway from one prescribed for weight management, with its own rules.
What if I do not qualify on the NHS?
Most people who want a GLP-1 medication in 2026 will not meet the narrow initial NHS gates, and the private route is much broader. GPhC-registered pharmacies and telehealth providers can prescribe to a wider group, and reported private costs sit in the region of £150 to £300 per month depending on the drug and dose. Treat that as a rough range rather than a fixed price, and use a registered UK pharmacy rather than an unregulated seller.
Where does fiber fit in?
This is a reimbursement guide, not medical advice, and fiber is a small part of the wider picture rather than the headline. We mention it only because constipation and other digestive changes are among the more commonly reported side effects of GLP-1 medication, and gentle, well-tolerated dietary fiber is one of the standard everyday tools people use to stay comfortable during treatment. If that is what brought you here, our research on why GLP-1 medications cause constipation and what actually helps goes into the evidence in detail. For specific products available in the UK, compared by type, dose, and cost, see our guide to the best fibre supplements UK.
The bottom line
In the UK, GLP-1 access is a story about gates, not percentages. Tirzepatide (Mounjaro) is being introduced through primary care from the highest-need patients outward, semaglutide (Wegovy) runs through specialist services, and the criteria differ by area and widen over time. If you do not yet qualify on the NHS, the private route is open but paid for in full. We refresh this guide every month so the eligibility detail stays current.